| Future Health Pharma GmbH - Nuvaxovid 0.5 ml, Injektionsdispersion | | 68473 | | 01 | | Nuvaxovid 0.5 ml | | Injektionsdispersion | | J07BX03 | | Covid-19 Vaccines | | 12.04.2022 | | |
| | Composition | | SARS CoV-2 rS NVX-CoV2373 5 µg, adjuvans Matrix-M: saponinum Fraction-A 42.5 µg et saponinum Fraction-C 7.5 µg ex Quillaja saponariae Molina extractum purificatum, cholesterolum, phosphatidylcholinum, int-rac-alpha-tocopherolum, kalii dihydrogenophosphas, kalii chloridum, dinatrii phosphas dihydricus, dinatrii phosphas heptahydricus, natrii dihydrogenophosphas monohydricus, natrii chloridum, polysorbatum 80, natrii hydroxidum q.s. ad pH, acidum hydrochloridum q.s. ad pH, aqua ad iniectabile q.s. ad praeparationem pro 0.5 ml corresp., natrium 4.0 mg, kalium 0.003 mg. | | Packungsbestandteile | | Injektionsdispersion | | | | | | Active Agent | Dose |
|---|
| Sars Cov-2 rs Nvx-Cov2373 | 5 µg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Cholesterol | | | | Disodium Phosphate Dihydrate | | | | Disodium Phosphate Heptahydrate | | | | Ex Quillaja Saponariae Molina Extractum Purificatum | | | | Int-Rac-Alpha-Tocopherolum | | | | Potassium Chloride | | | | Potassium Dihydrogenophosphate | | | | Sodium Chloride | | | | Sodium Dihydrogenophosphate Monohydrate | | | | Sodium Hydroxide | | | | Phosphatidylcholine | | | | Polysorbatum 80 | | | | Saponinum Fraction-A | 42.5 µg | adjuvans Matrix-M | | Saponinum Fraction-C | 7.5 µg | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| No entries have been found. |
|
|
